Personality & Trait Factors
Psychedelic research is increasingly examining the interplay between personality traits and therapeutic outcomes in various mental health conditions. Recent studies highlight how certain personality traits may influence the efficacy of psychedelic treatments, particularly in managing disorders like depression and anxiety.
Key Insights
- 1
High levels of openness are associated with more profound mystical experiences during psychedelic therapy, correlating with better treatment outcomes.
- 2
Individuals with neurotic tendencies may experience heightened vulnerabilities but can also achieve significant breakthroughs in depressive symptoms through guided psychedelic therapy.
- 3
Psychedelic-assisted therapy has shown particular promise for patients with comorbid personality and mood disorders, suggesting integrated treatment approaches may be beneficial.
What is Personality & Trait Factors?
Personality traits are enduring patterns of thoughts, feelings, and behaviours that are relatively stable over time and across situations. They can significantly impact an individual's susceptibility to mental health disorders and their response to treatment.
Common personality frameworks include the Big Five traits: openness, conscientiousness, extraversion, agreeableness, and neuroticism, each contributing to different mental health outcomes when considering psychedelic interventions.
Research indicates that traits such as high openness may enhance the positive effects of psychedelics, promoting experiences that lead to increased psychological flexibility and reduced symptoms of anxiety and depression.
Current Treatments
Standard treatments for personality disorders and related mental health conditions often include psychotherapy (such as cognitive behavioural therapy) and pharmacotherapy with antidepressants or mood stabilisers.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Personality & Trait Factors.
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Extensive clinical trials demonstrate psilocybin's efficacy in enhancing personality traits linked to improved mental health assessment scores. | Large | High | Consistent |
| MDMA MDMA-assisted therapy has shown consistent improvements in emotional openness and social functioning, critical for addressing personality disorders. | Large | High | Consistent |
| Ketamine While ketamine has shown efficacy in treating depression, its impact on personality structure requires further exploration. | Medium | Moderate | Inconsistent |
| LSD LSD has demonstrated potential in enhancing creativity and openness but with varying results in clinical settings. | Medium | Moderate | Inconsistent |
| Ayahuasca Evidence is emerging, but Ayahuasca's influence on personality traits remains under-researched. | Medium | Low | Inconsistent |
Psilocybin and Personality & Trait Factors
Psilocybin, the active compound in magic mushrooms, has been linked directly to positive changes in personality traits including increased openness and emotional resilience. Clinical studies reveal that psilocybin can induce profound mystical experiences that foster greater self-acceptance and adaptation, leading to lasting improvements in mental health among individuals with personality disorders.
MDMA and Personality & Trait Factors
MDMA, known for its empathogenic properties, enhances feelings of connection and emotional disclosure, pivotal in therapeutic settings. It facilitates communication and vulnerability, thus allowing patients to process trauma and navigate complex emotional landscapes related to their personality traits, particularly in context of PTSD and other anxiety disorders.
Clinical Outlook
The future of psychedelic treatment for personality and trait factors is promising, with ongoing research likely to refine our understanding of how personality influences therapeutic responses. Innovations in personalised treatment protocols may emerge, allowing for tailored psychedelic interventions that consider individual personality profiles.
Industrial Landscape
Key players in this field include MAPS (Multidisciplinary Association for Psychedelic Studies), the Beckley Foundation, and various academic institutions conducting clinical trials on psychedelic therapies.
Quick Indicators
Organisations
Search →University of Washington
At UW, researchers are working on clinical trials with psilocybin (provided by Usona). Dr Anthony Back, co-director of the University's Center for Excellence in Palliative Care, led a trial exploring the effects of psilocybin to alleviate the mental health burden inflicted on frontline healthcare workers throughout the COVID-19 pandemic. As Seattle became the largest city in the US to decriminalise psilocybin mushrooms in October 2021, and with ongoing legislative efforts at the state level, more research with psychedelics is anticipated and occurring at UW.
University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti. Research here is primarily focused on the pharmacology of psychoactive substances. Much of the clinical research exploring the effects of LSD is taking place at University Hospital Basel. Researchers here are exploring the potential of LSD to treat Cluster Headache, Major Depressive Disorder and anxiety associated with severe somatic diseases. Professor Liechti is also conducting studies comparing the acute effects of LSD, psilocybin and mescaline, and MDMA for fear extinction.
Maastricht University
While Maastricht University may not have a single dedicated psychedelic research group, various researchers at the university are investigating the effects of psychedelics. Early research exploring psychedelics at Maastricht focused on the dangers of MDMA. Now, research into the effects of microdosing is being led by Dr Kim Kuypers. Other research ongoing at the university is investigating cannabis as well as novel psychoactive substances (NPS). Maastricht is collaborating on research with the Beckley Foundation as well as Silo Pharma.
Psychedelic Data Society
The Psychedelic Data Society is a US-based citizen-science nonprofit managing the Psychedelic Data Project, a global harm reduction and research initiative that collects participant-contributed data to accelerate psychedelic science and inform evidence-based drug policy reform.
Quantified Citizen Technologies Inc.
Quantified Citizen Technologies Inc. is a Canadian privacy-centric mobile health research platform powering decentralized citizen-science studies; it built the world's first mobile app for psychedelic microdosing data collection (Microdose.me) with over 19,000 participants worldwide, whose findings were published in Nature Scientific Reports, and continues to host multiple psychedelic observational studies in partnership with MAPS, UBC, and researchers including Paul Stamets and James Fadiman.
People
Search →Federico Cavanna
Researcher in psychedelic science / neuroscientific researcher (exact current title not confidently verified)
He is a coauthor on multiple widely cited studies on psilocybin microdosing, DMT, and psychedelic use, helping characterize subjective, behavioral, and cognitive effects of psychedelics.
Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Aaron Klaiber
Doctoral researcher at the University of Basel
He appears as an author on multiple controlled human psychedelic studies spanning DMT, mescaline, MDMA, LSD, and psilocybin, suggesting a substantial role in contemporary psychopharmacology research.
Joost Breeksema
Postdoctoral researcher and Executive Director of the OPEN Foundation
He is a prominent psychedelic researcher and advocate whose work helps shape evidence-based psychedelic policy, ethics, and patient-centered understanding of psychedelic and ketamine/esketamine treatments.
Juliana Rocha
Doutoranda em Ciências Médicas / Saúde Mental at the Ribeirão Preto Medical School, University of São Paulo
She is a recurring coauthor on clinical psychedelic studies, especially ayahuasca trials on social anxiety, emotion recognition, personality, and social cognition, helping expand the human evidence base for psychedelic-assisted psychiatric research.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Michiel Van Elk
Associate Professor of Cognitive Psychology at Leiden University
Michiel van Elk is a prominent psychedelic science researcher known for rigorous, skeptical work on psilocybin, microdosing, expectancy effects, and the psychological mechanisms and risks of psychedelic experiences.
Jolien Veraart
Psychiatrist and PhD researcher at the University Medical Center Groningen / University of Groningen
She is a leading clinical researcher on ketamine and oral esketamine for treatment-resistant depression, including safety, efficacy, and real-world implementation.
Kate Godfrey
Research Associate at Imperial College London’s Centre for Psychedelic Research
Kate Godfrey is notable for contributing to leading human psychedelic research on microdosing, neuroimaging, and neuroplasticity at Imperial College London.
Erich Studerus
Psychologist and Scientific Director at fepsy Basel; Lecturer at FHNW
He is a recurring author on influential human psychedelic studies, especially on psilocybin, LSD, MDMA, and ayahuasca effects and predictors of response.
Connected Evidence
The latest clinical data and verified academic findings associated with Personality & Trait Factors.